A rational engineering strategy for designing protein a-binding camelid single-domain antibodies by Henry, K.A. (Kevin A.) et al.
RESEARCH ARTICLE
A Rational Engineering Strategy for
Designing Protein A-Binding Camelid Single-
Domain Antibodies
Kevin A. Henry1, Traian Sulea2, Henk van Faassen1, Greg Hussack1, Enrico O. Purisima2,
C. Roger MacKenzie1,3, Mehdi Arbabi-Ghahroudi1,3,4*
1 Human Health Therapeutics Portfolio, National Research Council Canada, 100 Sussex Drive, Ottawa,
Ontario, Canada, K1A 0R6, 2 Human Health Therapeutics Portfolio, National Research Council Canada,
6100 Royalmount Avenue, Montreal, Quebec, Canada, H4P 2R2, 3 School of Environmental Sciences,
University of Guelph, 50 Stone Road East, Guelph, Ontario, Canada, N1G 2W1, 4 Department of Biology,
Carleton University, 1125 Colonel By Drive, Ottawa, Ontario, Canada, K1S 5B6
*mehdi.arbabi@nrc-cnrc.gc.ca
Abstract
Staphylococcal protein A (SpA) and streptococcal protein G (SpG) affinity chromatography
are the gold standards for purifying monoclonal antibodies (mAbs) in therapeutic applica-
tions. However, camelid VHH single-domain Abs (sdAbs or VHHs) are not bound by SpG
and only sporadically bound by SpA. Currently, VHHs require affinity tag-based purification,
which limits their therapeutic potential and adds considerable complexity and cost to their
production. Here we describe a simple and rapid mutagenesis-based approach designed to
confer SpA binding upon a priori non-SpA-binding VHHs. We show that SpA binding of
VHHs is determined primarily by the same set of residues as in human mAbs, albeit with an
unexpected degree of tolerance to substitutions at certain core and non-core positions and
some limited dependence on at least one residue outside the SpA interface, and that SpA
binding could be successfully introduced into five VHHs against three different targets with
no adverse effects on expression yield or antigen binding. Next-generation sequencing of
llama, alpaca and dromedary VHH repertoires suggested that species differences in SpA
binding may result from frequency variation in specific deleterious polymorphisms, espe-
cially Ile57. Thus, the SpA binding phenotype of camelid VHHs can be easily modulated to
take advantage of tag-less purification techniques, although the frequency with which this is
required may depend on the source species.
Introduction
Therapeutic antibodies (Abs) represent the fastest-growing class of biologic drugs, with
expanding applications in cancer, chronic diseases and autoimmunity (reviewed in [1–3]).
Currently licensed biologics are most commonly fully human or humanized monoclonal
Abs (mAbs), with antigen-binding fragments such as Fab, F(ab’)2 and scFv making up a
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smaller proportion of the market [4]. Next-generation Ab therapeutics will likely exploit the
improved functional properties of molecularly engineered Abs, including bispecific Abs, Ab-
drug conjugates and Fc-variant Abs [1,4,5]. VHH single-domain antibodies (VHHs), the vari-
able domains of heavy-chain-only Abs produced naturally by camelid ungulates, may be
useful in the design of next-generation biologics as a result of their small size, stability and
modularity [6].
Full-length mAbs of all IgG subtypes can be easily purified by affinity chromatography, tak-
ing advantage of the high-affinity interactions between the IgG Fc and either staphyloccal pro-
tein A (SpA) or streptococcal protein G (SpG) [7]. Purification of Ab fragments bearing light
chains can be accomplished using protein L resins but purification of VHHs can be more com-
plex, often requiring recombinant fusion to an affinity tag sequence [8]. The presence of affin-
ity tags may impact protein folding, stability, solubility and aggregation state either directly or
indirectly via the elution process [9–14]; although such tags can be removed proteolytically
after purification, this process adds time and cost to the production pipeline. The gold standard
for tag-less purification of Ab fragments and VHHs is affinity chromatography using staphyloc-
cal protein A (SpA; reviewed in [15]), which contains binding sites for both the IgG Fc region
and variable regions of Ig heavy chains, with the specificity of the latter being restricted to
human IGHV3 gene family products [16–20] and their homologues in experimental animal
species [21,22]. The structural basis for binding of IGHV3 Abs by SpA was initially ascribed
broadly to residues in FR3, FR1 and possibly CDR2 [23,24] and later defined more precisely
using a co-crystal structure of a human IGHV3-encoded IgM in complex with SpA [25]. Bind-
ing appears to depend on thirteen Ig variable region residues at the direct interface with SpA,
which are almost universally conserved in germline IGHV3 genes, but can be lost as a result of
somatic hypermutation [17–19]. The importance of these residues has been inferred from
structural studies and comparison with sequences of non-SpA-binding Abs, but never formally
tested by mutagenesis.
Both Old World and NewWorld camelids produce both conventional and heavy-chain-
only Abs, which are rearranged during B-cell development from separate sets of germline vari-
able genes (VH and VHH genes, respectively [26]). Most camelid VHH genes are homologous
to human IGHV3-family genes and fall into 4–7 subfamilies [26,27], although recent work
suggests that human IGHV4 homologues may also exist that can be rearranged as both con-
ventional and heavy-chain only Abs [28]. Despite their homology to human IGHV3-family
genes, it has been reported that the majority of camelid VHHs are not bound by SpA [29,30],
although this may depend to some degree on species origin. At the amino acid level, the major
sequence differences between camelid VHHs and human IGHV3-family variable domains are
(i) the presence of hallmark VHH solubilizing residues located in FR2 at the interface with the
absent VL domain [27], (ii) an elevated frequency of intradomain disulfide bridges between
CDR3 and other regions, which may constrain VHH structure [31], (iii) the presence of vari-
ous other germline polymorphisms, depending on the individual VHH gene and (iv) high
somatic mutation rates [26]. However, it is unclear whether and how any of these sequence
characteristics should impact SpA binding. Thus, the purpose of this work was: (i) to identify
VHH residues required for SpA binding and evaluate their overlap with those defined for
human IGHV3 Abs [25], and (ii) to develop a strategy to confer SpA binding upon a priori
non-binding VHHs without compromising antigen binding. Our data confirm that SpA bind-
ing by VHHs is determined primarily by the same set of contact positions as in human IGHV3
mAbs, but also provide a comprehensive description of IGHV domain polymorphisms that
are permissive and non-permissive for SpA binding. These data can be used to engineer SpA-
binding VHHs using limited site-specific mutagenesis, with no adverse effects on expression
yield or antigen binding.
Engineered Protein A-Binding VH Hs
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Materials and Methods
Phage-displayed libraries and isolation of VHHs
The VHHs described in this report are directed against a variety of antigens and were initially
isolated from phage-displayed VHH libraries for reasons other than the study of SpA binding,
as described previously [32–38].
VHHmutagenesis
The amino acid sequences of five non-SpA-binding camelid VHHs (ICAM11-4, ICAM34-1
[39], IGF1R-4, IGF1R-5 [40] and AFAI [35]) were altered at specific FR positions, either indi-
vidually or in combination, either for humanization purposes or to confer SpA binding.
Constructs encoding the engineered VHHs were synthesized commercially in the pSJF2H
expression vector ([31]; GenScript, Piscataway, NJ or Life Technologies, Carlsbad, CA).
Soluble VHHmonomer and pentamer expression and purification
Wild-type or engineered VHH genes bearing BbsI/BamHI or BbsI/ApaI restriction sites were
cloned into pSJF2H or pVT2 expression vectors (for monomeric and pentameric expression,
respectively) as described [32,33,35]. 6×His- and c-Myc-tagged VHHmonomers and penta-
mers were expressed in E. coli TG1, extracted from the periplasm by osmotic shock and puri-
fied by immobilized metal affinity chromatography (IMAC) or protein A chromatography
using using HisTrap HP or HiTrap Protein A HP columns, respectively (GE Healthcare, Pis-
cataway, NJ; [32,33]). The integrity and aggregation status of soluble VHH monomers and pen-
tamers were assessed by SDS-PAGE, Western blotting and size exclusion chromatography
[32,33].
Surface plasmon resonance (SPR)
For screening of VHH monomers and pentamers for binding to immobilized SpA at a single
concentration, analyte proteins were used directly after purification by immobilized metal
affinity chromatography. For determination of binding affinities to immobilized antigen or
SpA, VHH monomers were purified by size exclusion chromatography using Superdex™ 75 or
200 10/300 GL columns (GE Healthcare) on an ÄKTA FPLC protein purification system (GE
Healthcare), and the monomer peaks collected in HBS-EP buffer (10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), pH 7.4, 150 mMNaCl, 3mM ethylenediaminetetra-
acetic acid (EDTA), 0.005% (v/v) surfactant P20; [32,33]). Briefly, either SpA (Thermo Fisher,
Waltham, MA), human ICAM-1 ectodomain (R&D Systems, Minneapolis, MN) or human
IGF1R ectodomain (R&D Systems) were immobilized on CM5 sensor chips using an amine
coupling kit (GE Healthcare) in 10 mM acetate buffer, pH 4.5, with surface densities of 609,
1348 and 476 resonance units, respectively. VHH monomers and pentamers were injected at
25°C in HBS-EP buffer at a flow rate of 20 μL/min on a Biacore 3000 instrument (GE Health-
care) at different concentration ranges, depending on the interaction (binding to SpA: 50 nM
—25 μM; binding to ICAM-1: 0.5 nM– 200 nM; binding to IGF1R: 0.1 nM– 10 nM). All sur-
faces were regenerated using 10 mM glycine, pH 2.0. Data were analyzed using BIAevaluation
4.1 software (GE Healthcare) and for affinity determinations, fitted to a 1:1 binding model.
In silico scanning mutagenesis of the SpA:VHH interaction
The co-crystal structure of a human IGHV3-encoded Fab in complex with domain D of SpA
(PDB ID: 1DEE) was used as a starting point for virtual scanning mutagenesis. Only one copy
of the IGHV3 domain (chain D) and the bound SpA fragment (chain G, corresponding to SpA
Engineered Protein A-Binding VH Hs
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domain D positions Asp8-Lys58 as numbered by Graille et al. [25]) were retained. The IGHV3
domain was first “camelized” by introducing four mutations in FR2: Val37Phe, Gly44Glu,
Leu45Arg and Trp47Ala. Hydrogen atoms were added to the resulting VHH:SpA complex and
adjusted to maximize H-bonding interactions. Structural refinement of the complex was then
carried out by energy-minimization using the AMBER force-field [41,42] with a distance-
dependent dielectric and infinite cutoff for non-bonded interactions. Non-hydrogen atoms
were restrained at their crystallographic positions with harmonic force constants of 20 and 5
kcal/(mol.A2) for the backbone and side-chain atoms, respectively. The resulting structure was
then used for single-point scanning mutagenesis simulations at the following positions of the
IGHV3 domain: 15, 17, 19, 57, 59, 64, 65, 66, 68, 70, 75, 81, 82a, and 82b (all positions using
Kabat numbering). We used three protocols (SIE-SCWRL [43–45], FoldX [46,47] and Rosetta
[48,49]) for modeling the structures and evaluating the energies of single-point substitutions of
the other 17 naturally-occurring amino acids (Cys and Pro excluded) at each of these 14 posi-
tions relative to the wild-type sequence. A consensus approach over specific versions of these
three protocols was applied for building and scoring IGHV3 mutants. Further technical and
implementation details of this approach and its component methods can be found in Sulea
et al. [50].
Next-generation DNA sequencing
Phagemid replicative form DNA from naïve and immune phage-displayed VHH libraries was
isolated from E. coli TG1 cells using QIAprep spin miniprep kits (QIAGEN, Valencia, CA).
Next-generation sequencing libraries were generated by two-step PCR amplification of VHH
genes and purified as previously described [51,52]. The final amplicons were pooled and puri-
fied from 1% (w/v) agarose gels using a QIAquick1 gel extraction kit (QIAGEN), desalted
using Agencourt AMPure XP beads (Beckman-Coulter, Pasadena, CA), then sequenced on a
MiSeq Sequencing System (Illumina, San Diego, CA) using a 500-cycle MiSeq Reagent Kit V2
and a 5% PhiX genomic DNA spike. From each sample, 0.1–2.1 million reads were generated,
of which 0.4×105–6.0×105 were used for analysis after assembly using FLASH (default parame-
ters; [53]) and quality filtering using the FAST-X toolkit with a stringency of Q30 over95%
of each read [54].
Results
Definition of VHH residues involved in SpA binding
Previous structural work [25] suggested the existence of a set of seven core SpA binding resi-
dues in human IGHV3 heavy-chain variable regions (positions 19, 65, 66, 68, 70, 81 and 82a;
all positions using Kabat numbering), with a lesser contribution of six additional contact resi-
dues (positions 15, 17, 57, 59, 64 and 82b). Parenthetically, these tend to be mostly conserved
in SpA-binding human and murine Abs and altered via germline variation or somatic hyper-
mutation in non-SpA-binding Abs [17–19], although neither the importance of each residue
nor the spectrum of tolerated substitutions has been rigorously tested by mutagenesis studies.
Overlay of the three-dimensional structures of a human IGHV3-encoded IgM heavy-chain
variable domain [25] and a llama VHH directed against Clostridium difficile toxin A [55]
showed strong overall conservation of these immunoglobulin folds (Fig 1).
To investigate whether the conserved SpA-binding residues in human IGHV3 Abs were
also important for VHH binding by SpA, we first determined the sequences of 55 VHHs
obtained in our lab along with an IGHV3-encoded human autonomous VH domain, HVH430
[56], and assessed their binding to immobilized SpA at a single concentration (250 nM) by
SPR (Fig 2; S1 Table). Many, but not all, camelid VHHs shared the human IGHV3 consensus
Engineered Protein A-Binding VH Hs
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sequence at all thirteen SpA contact residues, suggesting that they may interact in a similar way
with SpA. Complete or near-complete sequence conservation at some VHH positions (Gly15,
Ser17, Arg66, Ser70 and Gln81) among both SpA-binding VHHs and non-SpA-binding VHHs
prevented the assessment of their importance. In agreement with the conclusions of structural
studies [25] and a previous mutagenesis study [57], the salt bridge formed between the Asp res-
idue at position 36 of SpA domain D and the conserved Arg residue at VHH FR1 position 19
was indispensable, as its replacement with Lys, Ser or Thr abrogated SpA binding. Similarly,
replacement of core Gly65 with negatively charged Asp, or of core Asn82a with Asp or Ser, had
a destructive effect on SpA binding; the latter result is consistent with a previous mutagenesis
study [57] which found that substitution of Asn82a with Ala abrogated SpA binding. Surpris-
ingly, one VHH bearing a substitution of core Thr68 with Ala (VHH36) showed residual SpA
binding. However, since VHHs encoding Ala68 in combination with other substitutions did
not bind SpA, and the more conservative replacement of Thr68 with Ser reduced or ablated
SpA binding, we infer that that the limited polymorphisms tolerated at this position confer a
partial destabilizing effect on SpA binding.
In agreement with previous work [18,23], we found that a variety of residues (Thr, Arg and
Lys) were tolerated at the non-core VHH CDR2 position 57, although the full spectrum of tol-
erated residues could not be conclusively identified due to the co-occurrence of substitutions at
other positions (Fig 2; S1 Table). Conversely, the presence of Ala57 clearly ablated SpA bind-
ing, and surprisingly, two VHHs bearing Ile57, ICAM11-4 and VHH55, did not bind SpA; Ile57
is present in some germline human IGHV3 genes and was previously judged as permissive for
SpA binding by some groups [23,25] but not others [18]. There was some indication that VHH
Tyr59, which forms a H-bond with SpA Asp37 that was not considered a core interaction by
Graille et al. [25], might be essential, as its substitution with His or Val (in combination with
other substitutions in VHH26 and IGF1R-4) ablated SpA binding. Both reversal of charge at
Fig 1. Overlay of three-dimensional structures of a llama VHH (green, PDB ID: 4NC0) and a human
IGHV3 heavy chain variable domain (red, PDB ID: 1DEE) in complex with SpA domain D. Antigen-
binding CDRs are indicated.
doi:10.1371/journal.pone.0163113.g001
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the non-core VHH position 64 (Lys!Glu) and substitution of non-core Ser82b with Asn or
Arg appeared to be well tolerated, with no consistent detrimental effect on SpA binding.
Thus, the overall picture emerging from these data was that VHH interaction with SpA
depended primarily on the same set of residues as human IGHV3 Abs, albeit with: (i) an unan-
ticipated but minor degree of tolerance for variation at core position Thr68 and a broader toler-
ance at non-core positions Thr57, Lys64 and Ser82b; (ii) a potentially critical role for non-core
VHH position Tyr59; and (iii) a destructive effect of Ile at VHH position 57, in contrast to the
predictions of some previous studies. We attempted to corroborate these data using a set of
VHH pentamers [35] but found that the multivalent nature of the pentamer:SpA interaction
made it difficult to discriminate very weakly-binding from non-binding VHH pentamers (S1
Fig; S2 Table). We found no evidence to suggest that FR sequence polymorphisms outside the
previously defined SpA interface [25] played any role in SpA binding, with one notable excep-
tion (VHH39): this VHH did not bind SpA despite bearing the human IGHV3 consensus
sequence at all 13 SpA contact positions, but encodes a single-residue deletion at FR3 position
76. This provided the first preliminary evidence that FR3 positions 71–80 may influence struc-
turing of nearby SpA contact residues and play an indirect role in modulating SpA binding.
Fig 2. Identification of permissive and non-permissive residues for SpA binding at VHH SpA contact positions. 55 VHHs
of known sequence (FR sequences listed in S1 Table) were assayed for binding to immobilized SpA at a single concentration
(250 nM) by SPR and the number of response units bound at the end of the injection was recorded. The solid line represents
binding of HVH430 (17 RUs), an IGHV3-encoded human autonomous domain. For VHHs bearing the human IGHV3 consensus
residue (shown on the X-axis) at all 13 SpA contact positions, no data are plotted on the graph; instead, dotted lines are shown
representing the 95% confidence interval (CI) for mean SpA binding of “wild-type” VHHs bearing this consensus sequence. For
VHHs bearing single amino acid substitutions at any one of the 13 SpA contact positions, the relevant substitution is plotted on
the graph in green (substitution tolerated) if SpA binding fell within the 95% CI for wild-type VHHs (10–360 RUs), and red
(substitution not tolerated) if it fell below. For VHHs bearing multiple amino acid substitutions at SpA contact sites, substitutions
are plotted on the graph in blue.
doi:10.1371/journal.pone.0163113.g002
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SpA binding is reliably conferred to VHHs by humanization
The simplest possible strategy for rescuing SpA binding in non-SpA-binding VHHs would be
to revert any discrepancies at the 13 contact positions defined by Graille et al. [25] to the
human IGHV3 consensus sequence. This is always accomplished, by definition, through the
process of humanization, in which a llama VHH’s FRs are replaced almost entirely with those
of the most closely homologous human IGHV3 gene. To confirm that this strategy would be
successful, we took four a priori non-SpA-binding VHHs (ICAM11-4 and ICAM34-1, directed
against human ICAM-1; IGF1R-4 and IGF1R-5, directed against human IGF1R) and human-
ized them, thus reverting their FR sequences to human IGHV3 germline both at SpA contact
positions (Table 1) and elsewhere (S3 Table). A fifth example, AFAI (a VHH directed against
CEACAM6), was not humanized, but instead had two reversions incorporated via site-directed
mutagenesis (Glu64Lys, Asp82bSer).
SpA binding by these five camelid VHHs was initially extremely weak or undetectable, as
measured using single-concentration injections of 250 nM VHH over immobilized SpA in
SPR. However, in each case, VHH humanization (or in the case of AFAI, reversion of both
Glu64 to Lys and Asp82b to Ser) conferred SpA binding (S2 Fig) that was sufficient to enable
their purification by SpA affinity chromatography (S3 Fig). In three of four cases, expression
yields of the humanized VHHs after IMAC purification were reduced by 50% or more com-
pared to their wild-type llama counterparts (Table 2, left vs. middle columns), and in one
case (ICAM11-4), the humanized VHH had a ~20-fold loss of affinity for its cognate antigen
(Table 3, left vs. middle columns). Thus, perhaps unsurprisingly, SpA binding could be
successfully introduced into five a priori non-SpA-binding VHHs by humanization,
although this came at the cost of reduced expression yield, and in one case, impaired antigen
recognition.
Table 1. FR sequences of five non-SpA-binding VHHs at SpA contact positions.
VHH VHH Position
15 (G) 17 (S) 19 (R) 57 (K/I/T) 59 (Y) 64 (K) 65 (G) 66 (R) 68 (T) 70 (S) 81 (Q) 82a (N) 82b (S)
ICAM11-4 G S R I* Y K G R T S Q N S
ICAM34-1 G S R A* Y K G R T S Q N G*
IGF1R-4 G S R T V* K D* R T S Q N S
IGF1R-5 G S R A* Y K G R T S Q N N*
AFAI G S R T Y E* G R T S Q N D*
*Residues were reverted to the human IGHV3 germline consensus during humanization
doi:10.1371/journal.pone.0163113.t001
Table 2. Expression yields (mg/L) in E. coli of wild-type llama VHHs vs. their humanized or SpA-engineered counterparts.
VHH Wild-type Humanized SpA-engineered
ICAM11-4 20.0 4.5 17.0
ICAM34-1 21.0 7.0 25.0
IGF1R-4 9.0 4.5 6.0
IGF1R-5 14.0 11.0 12.0
AFAI 6.0 n.d. 4.0
n.d., not determined
doi:10.1371/journal.pone.0163113.t002
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SpA binding can be conferred to VHHs by limited site-directed
mutagenesis without negatively impacting expression yield or antigen
binding
To determine whether SpA binding could be restored in non-SpA binding VHHs without
incurring the negative consequences of humanization on expression yield and antigen binding,
and to better understand the relative impacts of individual substitutions on SpA binding, we
took the same five non-SpA binding VHHs as above and reverted any discrepancies at the 13
SpA contact positions (Table 1) to the human IGHV3 consensus by site-directed mutagenesis.
In one case (ICAM34-1), we also reverted an unusual Pro at position 75 to the human IGHV3
consensus Lys, based on the hypothesis that this Pro residue might affect structuring of sur-
rounding SpA contact residues. Substitutions were incorporated either singly or in all possible
combinations, and the SpA-binding affinities of the resulting engineered VHHs were then
determined by SPR.
In the case of ICAM11-4, a single substitution (Ile57Thr) was sufficient to restore 9.0 μM
affinity for SpA (Table 4; in this table and hereafter, SpA-engineered VHHs (underlined) are
defined as the variants bearing the minimal substitutions from wild-type sequences required to
restore SpA binding), near to the wild-type affinity range of 1–5 μM described for human
IGHV3-encoded VH domains [56]. In the case of ICAM34-1, two reversions (Ala57Thr and
Pro75Lys) were necessary to recover any degree of SpA binding (9.6 μM), which was improved
slightly by a third reversion (Gly82bSer, 4.5 μM). Likewise, two substitutions (Val59Tyr and
Asp65Gly) were required to restore SpA binding (1.5 μM) to IGF1R-4, confirming the critical
nature of the consensus residue at both of these positions for interaction with SpA. In the case
of IGF1R-5, a single substitution (Ala57Thr) conferred 3.7 μM affinity for SpA, with no further
affinity improvement obtained by reversion of position 82b from Asn to Ser. Finally, reversion
of Asp82b to Ser in AFAI restored weak SpA binding (11.0 μM), which was further improved
with the additional reversion of Glu64 to Lys (0.6 μM). This suggested a cumulative defect of
both substitutions in the wild-type VHH, with Asp82b conferring more significant binding
impairment than Glu64.
In summary, at least in the five examples above, SpA binding could be conferred to non-
SpA binding VHHs using limited numbers (1–3) of amino acid substitutions. The resulting
engineered VHHs bound SpA with affinities similar to those of human IGHV3-encoded Fabs,
could be purified by SpA affinity chromatography (S3 Fig), and had expression yields after
IMAC purification that were indistinguishable from their non-SpA binding counterparts
(Table 2, left vs. rightmost column). In the case of ICAM11-4, the engineered SpA-binding
VHH retained full affinity for ICAM-1, unlike the humanized VHH (Table 3, middle vs. right
Table 3. Affinities for cognate antigen (pH 7.4, 25°C) of wild-type llama VHHs vs. their humanized or SpA-engineered counterparts.
VHH Wild-type Humanized SpA-engineered
ICAM11-4 0.9 nM 17 nM 1.3 nM
ICAM34-1 32 nM 26 nM n.d.a
IGF1R-4 0.3 nM 0.4 nM n.d.a
IGF1R-5 0.8 nM 0.9 nM n.d.a
AFAI +b n.d. +b
n.d., not determined
aAfﬁnities were not determined on the assumption that since no loss of afﬁnity was observed in the humanized VHH, SpA-engineered VHHs (bearing fewer
changes from wild-type) would also retain full afﬁnity for antigen.
bAfﬁnities were not determined using monomeric VHH; rather, binding of wild-type and SpA-engineered VHH pentamers are shown in S4 Fig.
doi:10.1371/journal.pone.0163113.t003
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columns). The data provided from these mutagenesis studies also expanded our understanding
of the spectrum of permissive and non-permissive VHH residues for SpA binding, which are
listed in Table 5, and clearly supported the hypothesis that residues outside the SpA contact
interface such as Pro75 can indirectly modulate SpA binding.
3.4. In silicomodeling of the SpA:VHH interaction by virtual mutagenesis
To support and extend the experimental results above, we carried out a computational assess-
ment of the effects of virtual mutagenesis of VHH SpA contact residues on SpA binding (Fig 3
and Table 5). We used a consensus approach for mutant building and scoring that has been
found to afford improved ranking of Ab:antigen binding affinities relative to various individual
methods when applied to over 200 single-point antibody mutants of the SiPMAB database
curated from the literature [50]. We used the published SpA:IGHV3 Fab structure [25] as the
basis for in silico analyses, but prior to virtual mutagenesis excluded the light chain from con-
sideration and “camelized” the human IGHV3 domain by substitution of FR2 Val37Phe,
Gly44Glu, Trp47Ala and Leu45Arg. The results of in silicomutagenesis provided an explana-
tion for the almost complete conservation of Gly15, core Gly65 and core Arg66 in VHHs, since
substitution of these residues was predicted to drastically destabilize VHH folding; the back-
bone phi-psi dihedral angles of Gly15 and Gly65 are (92, -18) and (92, -20), respectively, in the
4NC0 crystal structure and are high-energy regions for non-glycine amino acids. Conversely,
Ser17 and core Ser70 were predicted to tolerate substitution with a variety of residues despite
being almost totally conserved in VHHs. In the case of core VHH Gly65, experimental evidence
contradicted computational predictions of fold destabilization by substitution with Asp, as this
residue was observed in three VHHmonomers and one VHH pentamer (S1 and S2 Tables). In
agreement with experimental data, core VHH Arg19 was critical for interaction with SpA, and
Table 4. Affinities for SpA (pH 7.4, 25°C) of wild-type llama VHHs vs. their SpA-engineered
counterparts.
VHH Wild-type SpA-engineered (KD)
ICAM11-4 n.b. I57T (9.0 μM)*
ICAM34-1 n.b. A57T (n.b.)
P75K (n.b.)
G82bS (n.b.)
A57T, P75K (9.6 μM)
A57T, G82bS (n.b.)
P75K, G82bS (n.b.)
A57T, P75K, G82bS (4.5 μM)*
IGF1R-4 n.b. V59Y (n.b.)
D65G (n.b.)
V59Y, D65G (1.5 μM)*
IGF1R-5 n.b. A57T (3.7 μM)*
N82bS (n.b.)
A57T, N82bS (3.5 μM)
AFAI n.b. E64K (n.b.)
D82bS (11.0 μM)
E64K, D82bS (0.6 μM)*
n.b., no binding
*SpA-engineered VHHs (deﬁned as the variants bearing the minimal substitutions from wild-type sequences
required to restore SpA binding) are underlined
doi:10.1371/journal.pone.0163113.t004
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could not be substituted even conservatively by Lys. Also in line with experimental data, mod-
erate but potentially non-destructive reductions of SpA binding were predicted when VHH
core Thr68 was substituted with Ser, Ala and several other residues; similar trends were
observed for core Gln81 and Asn82a. Virtual mutagenesis predicted a critical role for non-core
VHH positions 57 (Thr, Lys, and Arg) and Tyr59, a negligible role for non-core VHH position
Lys64 and variable effects of Ser82b substitution, with minor loss of binding resulting from
Table 5. Spectrum of residues tolerated at VHH SpA contact positions, as demonstrated by experimental data or as predicted by in silico
mutagenesis.
VHH Position Experimentally Validated Computationally Predicted
Tolerated Not tolerated Tolerated Not tolerated
15 (G) G, Da - G All others
17 (S) S, Aa - Many -
19 (R) R K, S, Aa, Qa R All others
57 (K/I/T) K, R, T A, I K, R, T All others
59 (Y) Y V Y All others
64 (K) K (E)* - Many -
65 (G) G D G All others
66 (R) R - R All others
68 (T) (A) S I, M, V Many
70 (S) S - Many I, T, V
75 (K) A, E, K, Q, R P Many I, T, V
81 (Q) Q - M, R Many
82a (N) N D, S, Aa I, L, M, V Many
82b (S) S, N (G) D Many Many
Residues in brackets are tolerated but result in some loss of binding
aData from Fridy et al. [57]
doi:10.1371/journal.pone.0163113.t005
Fig 3. Effect of in silico scanningmutagenesis of VHH SpA contact residues on VHH folding and SpA binding. Consensus Z-scores for
SpA binding were calculated over the SIE-SCWRL, FoldX and Rosetta protocols for mutations to 18 amino acids (shown at the top) at
14 VHH positions (shown on the left). Predicted change to ΔG (free energy of binding, kCal/mol) for SpA binding to VHH are shown
numerically and colored in shades of red or blue for single-point mutations predicted to strengthen or weaken SpA binding, respectively,
relative to the wild-type amino acid corresponding to the human IGHV3 sequence. Mutations predicted by FoldX to destabilize VHH folding by
more than 10-fold relative to parental IGHV3 sequence are highlighted in black shading. See Materials and Methods and Sulea et al. [50] for
further details.
doi:10.1371/journal.pone.0163113.g003
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Asn substitution and more pronounced defects resulting from substitution with Gly or Asp.
Interestingly, VHH position 75 was predicted to tolerate substitution with most residues except
those with beta-branched side chains, which probably disrupt the H-bonded turn of the FR3
loop at this location. We speculate that the effect of Pro substitution at this position has a
similar effect and the incurred local misfolding may be propagated to adjacent SpA contact
residues.
Overall, the experimental and computational data were congruent and together supported
the classification of SpA contact residues of VHHs into three categories: (i) critical for folding
(Gly15, Gly65, Arg66) and/or binding (Arg19, Tyr59, Gly65); (ii) partially permissive to spe-
cific substitutions (Thr68, Gln81, Asn82a, Thr/Lys/Arg57, Ser82b) and generally tolerant to
many substitutions (Ser17, Ser70, Lys64). For VHH residues falling into the second and third
categories, however, the spectrum of amino acids predicted computationally to be tolerated at
each position could not be validated experimentally using the available data.
Next-generation DNA sequencing of camelid VHH repertoires suggests
that species differences in SpA binding may arise from differential
frequency of Ile57 polymorphism
SpA binding is observed rarely in VHHs of dromedary origin and more commonly in those of
llama origin, although a detailed comparison of the frequency of SpA binding by species has
yet to be published [30]. To identify potential explanations at the level of protein sequences
that might account for this observation, we used next-generation sequencing technology to
interrogate four VHH repertoires to variable depths (0.4–6.0×10
5 reads; S4 Table). The source
of the VHH repertoires were either lymphocytes derived from three individual llamas or a sin-
gle pooled sample of alpaca, camel and llama lymphocytes [34].
As shown in Fig 4A, there was no general defect in SpA binding evident from the sequences
of VHH repertoires of camels and alpacas. The proportion of VHH sequences bearing the
human IGHV3 consensus sequence at SpA contact positions was broadly similar in all four
repertoires, except at position 57, where Ile was much more frequently present in dromedary
and/or alpaca VHHs (llama repertoire: ~5% vs. mixed llama, alpaca and camel repertoires:
~22%). A major difference was observed in the frequency of putative CDR1-CDR3 intrado-
main disulfide bonds, as indicated by the simultaneous presence of Cys residues at any position
within both these regions, which were almost entirely absent in the repertoires of llamas but
very frequent in the mixed-species repertoire (Fig 4B). To confirm that CDR1-CDR3 disulfide
bridging had no effect on SpA binding, we ablated this disulfide from a non-SpA-binding
dromedary VHH as well as introduced it into the engineered SpA-binding variant of the same
VHH (Ile57Thr; S5 Table). Neither introduction nor ablation of the CDR1-CDR3 disulfide
bridge had any impact on SpA binding, at least in the case of the single dromedary VHH tested
here.
Discussion
SpA affinity chromatography has become the purification method of choice for most antibody
manufacturers over the last 15 years, especially in the therapeutic Ab pipeline [8]. For many
applications, VHHs are fused to mouse or human Fc regions for mammalian cell production
and easily purified using conventional methods [58]. However, in some circumstances (e.g., in
vivo imaging [59]; co-crystallization [60]; tumor targeting requiring tissue penetration [61]),
the small size of the VHHmolecule is essential, and the addition of affinity tags for purification
may detract from the stability and homogeneity of the final product. The same is true of VHH
pentamers, and the starting point for this work was the observation that His- and/or Myc-
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tagged pentamers had increased propensity for aggregation and non-specific binding than
their untagged counterparts. Thus, tagless strategies for VHH purification are highly desirable.
Here, we present a detailed description of the sequence features of SpA-binding and SpA-
non-binding VHHs, and by extension, the features governing the interaction between SpA
and other immunoglobulin VH domains. Our results have important distinctions from those
inferred from the SpA:Fab crystal structure [25]. First, we found that several core positions in
the VHH:SpA interface can tolerate a limited degree of polymorphism without ablating SpA
binding (shown experimentally: Thr68; predicted computationally: Thr68, Ser70, Gln18,
Asn82a). Second, on the basis of both experimental data and computational structural model-
ing, we found that non-core VHH Thr/Lys/Arg57 and Tyr59 are indispensable for SpA binding,
and that Ile57 had a destructive effect on SpA binding. Third, we found that VHH Pro75 exerts
a destabilizing effect on SpA binding, potentially by altering the conformation of FR3 suffi-
ciently to displace SpA contact residues some distance away. Given this surprising finding, a
potential role for additional VHH polymorphisms outside the SpA interface in determining
SpA binding cannot be ruled out. However, the fact that a three amino acid insertion in the
FR3 of VHH52 (S1 Table) did not impair SpA binding suggests that epistatic effects involving
“action at a distance”may be rare.
In the analyses presented here, we did not attempt to rank the relative effects of individual
VHH substitutions on SpA binding, instead opting to categorize them dichotomously as per-
missive or non-permissive for SpA binding (Table 5). The rationale for this decision was two-
fold. First, several substitutions were observed experimentally in only a single VHH, and
their effects may depend on the sequence background and presence of other polymorphisms.
Fig 4. Next-generation DNA sequencing of llama andmixed-species (alpaca, camel, llama) VHH repertoires and analysis of SpA
contact residues. (A) Frequency of SpA-permissive residues at contact positions in llama vs. mixed-species VHH repertoires. Triangles
represent individual llama repertoires, squares represent a single pooled mixed-species repertoire, and horizontal lines represent the mean.
Residues permissive for SpA binding are indicated on the X-axis. (B) Frequency of putative CDR1-CDR3 intradomain disulfide bond in llama
vs. mixed-species VHH repertoires. Horizontal lines represent the averages.
doi:10.1371/journal.pone.0163113.g004
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Second, the weak overall affinity of the SpA:VHH interaction makes determinations of mono-
valent binding strength challenging below a certain threshold, and weak residual binding is dif-
ficult to rule out experimentally; this was clearly evident in comparisons of SpA binding of
VHH monomers and pentamers bearing similar sequences. Nevertheless, the overall consis-
tency between experimental data and computational predictions, as well as with the limited
mutagenesis data of Fridy et al. [57], provides a strong degree of confidence in the general
effects of many of the substitutions described here. We caution, however, that computational
predictions of minor or moderate reductions in SpA binding were not always accurate in the
degree of their effects, and that the safest course is to revert all VHH contact positions back to
the human IGHV3 consensus, even if some of the original polymorphisms might have been
tolerated.
Using next-generation DNA sequencing of llama, alpaca and dromedary VHH repertoires,
we found that the most likely explanation for non-SpA binding of dromedary VHHs was the
presence of non-permissive residues at SpA contact positions, especially Ile57. Since the com-
parison in our analysis was between llama and mixed-species repertoires, the frequency of dele-
terious polymorphisms detrimental to SpA binding, including Ile57, is likely even higher than
shown here in the repertoires of alpacas and/or dromedaries. It remains unclear whether such
differences arise through germline polymorphism or somatic mutation, although comparison
of germline [26] and rearranged [27] camelid VHH sequences favours the latter hypothesis.
Also unclear are the reasons why Ile57 should be a hotspot for mutation in dromedaries and/or
alpacas, but not llamas.
On the basis of these data, we propose the following general strategy for conferring SpA
binding upon camelid VHHs: (i) ensure that FR1 residues Gly15, Ser17 and Arg19 are present
and revert any discrepancies to this consensus; (ii) ensure that CDR2 residue Thr/Lys/Arg57 is
present and revert any discrepancies to this consensus; (iii) ensure that FR3 residues Tyr59,
Lys64, Gly65, Arg66, Thr68, Ser70, Gln81, Asn82a, Ser/Asn82b are present and revert any dis-
crepancies to this consensus; and (iv) closely examine FR3 positions 71–80 for Pro residues
(especially at position 75) and unusual deletions and revert these to the nearest human IGHV3
germline residue. We have found no evidence to suggest that any of the substitutions intro-
duced following these rules affect the expression yield, solubility, stability or aggregation status
of VHHs, and while some may not be essential for SpA binding, they are also not harmful.
While there were no affinity penalties resulting from these substitutions for any of the five
VHHs shown here, the necessity of restricting CDR2 position 57 diversity to Thr, Lys or Arg
may compromise the affinity of other VHHs.
In conclusion, we have identified the sequence hallmarks responsible for determining cam-
elid VHH binding by SpA, which provide an explanation for species differences in VHH SpA
reactivity. We used this information to develop a strategy for engineering VHHs to introduce
SpA binding and enable their tagless purification by SpA chromatography. This strategy may
also apply to Ab fragments of other species, or at least those that share homology with human
IGHV3 Abs.
Supporting Information
S1 Fig. Binding of VHH pentamers at 100 nM to immobilized SpA by SPR. Each pentamer
(FR sequences listed in S2 Table) was injected for 2 min and the number of response units
bound at the end of the injection was measured. For pentamers bearing the human IGHV3
consensus residue at all 13 SpA contact positions, no residues are plotted on the graph; instead,
dotted lines are shown representing the 95% confidence interval (CI) for mean SpA binding of
wild-type pentamers bearing this consensus sequence. For pentamers bearing single amino
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acid substitutions at any one of the 13 SpA contact positions, the relevant substitution is plotted
on the graph in green (substitution tolerated) if SpA binding fell within the 95% CI for wild-
type pentamers, and red (substitution not tolerated) if not. For pentamers bearing multiple
amino acid substitutions at SpA contact sites, substitutions are plotted on the graph in blue.
We used a verotoxin B-irrelevant peptide fusion as a negative control to rule out potential
interactions between SpA and the pentamerization domain (data not shown).
(TIF)
S2 Fig. SpA binding by SPR of four llama VHHmonomers (ICAM11-4, ICAM34-1, IGF1R-
4 and IGF1R-5; dotted lines) and one llama VHH pentamer (AFAI; dotted line) along with
their humanized counterparts (solid line). VHHmonomers and pentamers (250 nM) were
injected over immobilized SpA for 2 min and allowed to dissociate as described in methods.
(TIF)
S3 Fig. Representative chromatogram overlay of purification of llama, humanized and
SpA-engineered ICAM11-4 VHH. All three VHHs were produced in E. coli TG1 cells in 1L
2×YT overnight cultures grown at 37°C. VHHs were extracted from periplasmic space by
osmotic shock and purified using a HiTrap Protein A HP column on an ÄKTA FPLC protein
purification system (GE Healthcare).
(TIF)
S4 Fig. Binding of wild-type or SpA-engineered AFAI VHH pentamers at either 1 nM (A)
or 50 nM (B) to immobilized CEACAM6 N-terminal domain by SPR. VHH pentamers were
injected over immobilized CEACAM6 N-terminal domain for 3 min and allowed to dissociate
as described in methods.
(TIF)
S1 Table. FR sequences of SpA-binding and non-SpA-binding VHHmonomers.
(DOCX)
S2 Table. FR sequences of SpA-binding and non-SpA-binding VHH pentamers.
(DOCX)
S3 Table. FR sequences of five non-SpA-binding VHHs and their humanized SpA-binding
counterparts.
(DOCX)
S4 Table. Metrics for Illumina MiSeq NGS data used in this study.
(DOCX)
S5 Table. FR and CDR sequences of a SpA-binding (Thr57) and non-SpA-binding (Ile57)
dromedary VHH and effect of CDR1-CDR3 disulfide bridge on SpA binding.
(DOCX)
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